FS Development Corp. II (FSII): Price and Financial Metrics


FS Development Corp. II (FSII): $9.80

-0.20 (-2.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

FSII Stock Price Chart Interactive Chart >

Price chart for FSII

FSII Price/Volume Stats

Current price $9.80 52-week high $15.05
Prev. close $10.00 52-week low $9.64
Day low $9.69 Volume 289,100
Day high $10.16 Avg. volume 99,758
50-day MA $11.64 Dividend yield N/A
200-day MA $10.43 Market Cap 203.12M

FS Development Corp. II (FSII) Company Bio


FS Development Corp. II operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.


FSII Latest News Stream


Event/Time News Detail
Loading, please wait...

FSII Latest Social Stream


Loading social stream, please wait...

View Full FSII Social Stream

Latest FSII News From Around the Web

Below are the latest news stories about FS Development Corp II that investors may wish to consider to help them evaluate FSII as an investment opportunity.

Pardes Biosciences Debuts as a Publicly Traded Company Focused on Oral Antiviral Therapies to Potentially Treat and Prevent COVID-19

Pardes Biosciences Main Protease Pardes Biosciences Main Protease PBI-0451 Pardes Biosciences PBI-0451 Oral Antiviral Pill Pardes NASDAQ Listing Pardes Biosciences Debuts on NASDAQ PRDS Nasdaq Listed Pardes Biosciences debuts on NASDAQ under ticker symbol "PRDS" Ongoing Phase I trial shows potential for stand-alone, unboosted agent against COVID-19 Gross proceeds made available to Pardes Biosciences from transaction totaled approximately $274 million, combining approximately $199 million of fund

Yahoo | December 27, 2021

Startup with potential Covid-fighting pill eyes $300M SPAC deal

The small company, formed as the Covid pandemic started to take hold in February 2020, could take its oral drug into a late-stage clinical trial as early as the first half of next year.

Yahoo | December 22, 2021

FSII and Pardes Biosciences Move Towards Merger With the Goal of Tackling COVID-19 via an Oral Antiviral for Treatment and Prevention of SARS-CoV-2 Infections

SAN FRANCISCO & LARKSPUR, Calif., December 21, 2021--FSII and Pardes Biosciences move towards merger with the goal of tackling COVID-19 via an oral antiviral.

Yahoo | December 21, 2021

FS Development Corp. II (NASDAQ:FSII) Stock Passes Above 200 Day Moving Average of $0.00

Shares of FS Development Corp. II (NASDAQ:FSII) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.00 and traded as high as $10.79. FS Development Corp. II shares last traded at $10.79, with a volume of 169,882 shares changing hands. The businesss 50 day moving []

Dakota Financial News | December 16, 2021

FS Development Corp. II (NASDAQ:FSII) Share Price Crosses Above Two Hundred Day Moving Average of $0.00

FS Development Corp. II (NASDAQ:FSII)s share price passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.00 and traded as high as $10.79. FS Development Corp. II shares last traded at $10.79, with a volume of 169,882 shares changing hands. The stocks 50 day simple []

Transcript Daily | December 15, 2021

Read More 'FSII' Stories Here

FSII Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year -1.51%
3-year N/A
5-year N/A
YTD N/A
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4939 seconds.